Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Gastro-Oesophageal Cancer: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Gastro-Oesophageal Cancer: 1 US clinical trial tracked, none currently recruiting.

Gastro-Oesophageal Cancer is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Australasian Gastro-Intestinal Trials Group, running 1 of these trials.

Enrollment posture brief

Registry condition gastro-oesophageal-cancer

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Gastro-Oesophageal Cance (th…0%
Open-enrollment share among volume-matched conditions near Gastro-Oesophageal Cancer

Gastro-Oesophageal Cancer has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gastro-Oesophageal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gastro-Oesophageal Cancer is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Named interventions

Most-linked intervention names on Gastro-Oesophageal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Irinotecan Drug
1 trials
Nivolumab Biological
1 trials
Regorafenib Drug
1 trials
Paclitaxel Drug
1 trials
Docetaxel Drug
1 trials

US sites by state

Facility locations filed on Gastro-Oesophageal Cancer trials. A trial with sites in several states counts in each.

Washington 1 trials
South Dakota 1 trials
Kentucky 1 trials
Iowa 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gastro-Oesophageal Cancer page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastro-Oesophageal Cancer condition card totals 1 registered trials; most-linked intervention Irinotecan; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.